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Abstract Although relatively uncommon individually, the
various causes of hypophosphataemic rickets have provided
an impetus for unravelling the mechanisms of phosphate
homeostasis and bone mineralisation. Over the past
10 years, considerable advances have been made in
establishing the gene mutations responsible for a number
of the inherited causes and in understanding the mecha-
nisms responsible for tumour-induced osteomalacia/rickets.
The most exciting aspects of these discoveries have been
the discovery of a whole new class of hormones or
phosphatonins which are thought to control phosphate
homoeostasis and 1 alpha-hydroxylase activity in the
kidney, through a bone–kidney–intestinal tract axis. Al-
though our understanding of the interrelationships is far
from complete, it raises the possibilities of improved
therapeutic agents in the long-term, and has resulted in
improved diagnostic abilities in the short-term.
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Abbreviations
ADHR Autosomal dominant hypophosphataemic rickets
ARHR Autosomal recessive hypophosphataemic rickets
DMP Dentin matrix protein
FGF23 Fibroblast growth factor-23
FRP4 Frizzled related protein-4
HHRH Hereditary hypophosphataemic rickets with
hypercalciuria
MEPE Matrix extracellular phosphoglycoprotein
NaPi-I Na-dependent phosphate cotransporter-1
NaPi-II Na-dependent phosphate cotransporter-2
NaPi-III Na-dependent phosphate cotransporter-3
PHEX Phosphate-regulating gene with homologies to
endopeptidases on the X-chromosome
Pi Inorganic phosphate
PTH Parathyroid hormone
TIO Tumour-induced osteomalacia
XLH X-linked hypophosphataemic rickets
1,25
(OH)2D
1,25-dihydroxyvitamin D
Introduction
Over the past decade, considerable advances have been
made in our understanding of the pathogenesis of the
various forms of hypophosphataemic rickets, although there
are still many gaps in our knowledge. These advances have
led to improved diagnosis and, in some situations,
improved management. They have also gone some way in
helping to unravel the mysteries surrounding bone miner-
alisation, the control of serum phosphorus concentrations
and phosphorus homoeostasis. This paper briefly describes
the control of serum phosphorus (Pi) concentrations in
children and then discusses the advances made in elucidat-
ing the pathogenesis of various forms of hypophosphatae-
mic rickets, concentrating on those associated with isolated
renal tubular Pi loss.
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e-mail: john.pettifor@wits.ac.zaThe control of serum phosphorus
The normal range of serum Pi changes from the neonatal
period through adolescence to reach adult values towards the
end of puberty. Pi concentrations are highest in the neonatal
period (1.88–2.4 mmol/l), but fall rapidly in the first few
months of life and then more slowly to reach childhood
levels (1.45–1.80 mmol/l). The concentrations then remain
fairly constant until adolescence, when values fall to adult
values (0.8–1.45 mmol/l). Unlike dietary calcium, ingested
phosphate is generally efficiently absorbed (65–90% in
children) from the gastrointestinal tract, although complex
plant phosphate (phytate) is almost totally excreted. The
majority of dietary Pi is absorbed by passive concentration-
dependent processes, but the active metabolite of vitamin D
(1,25-dihydroxyvitamin D(1,25(OH)2D)) does increase the
intestinal Pi absorption marginally.
Serum Pi homeostasis is maintained largely through the
control of renal phosphate reabsorption, and, in a steady
state, urine Pi excretion reflects dietary intake. A number of
factors influence the renal tubular reabsorption of Pi, such
as dietary phosphorus content, and parathyroid hormone
(PTH), growth hormone (insulin-like growth factor 1) and
thyroid hormone concentrations, although these latter two
hormones probably do not play a major role in the short-
term control of serum Pi concentrations, but, rather,
determine long-term concentrations.
The major rate-limiting factor in the renal reabsorption of
Pi is the Pi transporter located at the brush border membrane
of the proximal renal tubular cells. Eighty-five percent of Pi
reabsorption normally takes place in the proximal renal
tubule. There are three genes encoding for sodium-dependent
phosphate co-transporters; NaPi-I–NaPi-III [11]. NaPi-IIa
and NaPi-IIc are the major transporters in the proximal
tubule and are regulated by PTH, which internalises the
transporters and increases their catabolism, thus, reducing
Pi reabsorption. Recently, it has been established that
fibroblast growth factor-23 (FGF23) is also a potent
r e g u l a t o ro fN a P i-II activity. FGF23 is one of the newly
discovered phosphatonins (hormones that control serum Pi
concentration through stimulating phosphaturia) and will
be discussed in more detail later. The co-transporter, NaPi-
IIc, was originally thought to play a lesser role in normal
Pi homeostasis, but this has been questioned recently.
As the renal handling of Pi plays such a vital role in the
maintenance of serum Pi concentration, it is important in
situations of both hyper- and hypophosphataemia to assess
renal tubular Pi reabsorption (or, more appropriately, the
tubular maximum for Pi reabsorption (TmP/GFR)) in order
to establish the pathogenesis. This is easily done by
measuring the renal phosphate handling on a morning
fasting but untimed urine specimen (measuring urinary Pi
and creatinine concentrations), together with the simulta-
neous measurement of serum Pi and creatinine. Tubular
reabsorption is calculated as [1−(UPi×PCr)/(UCr×PPi)]×100,
where UPi and PPi are the urine and serum Pi concen-
trations, respectively, and UCr and PCr are the
corresponding creatinine concentrations. As appropriate
renal tubular reabsorption is dependent on the serum Pi
concentration, Walton and Bijvoet [24] created a nomogram
to calculate the tubular maximum for Pi reabsorption
(TmPi/GFR), which is similar in concept to the renal
glucose threshold; in other words it is the serum Pi
concentration at which Pi begins to appear in the urine.
The nomogram described above is not applicable to
children, but paediatric age-specific normal ranges have
been developed by Alon and Hellerstein [1]. In normal
children, the TmPi/GFR should be similar to the normal
values of serum Pi at a particular age. A calculated TmPi/
GFR below this range indicates inappropriate renal Pi loss
(similar to that which occurs in hyperparathyroidism or
renal tubular Pi leaks, e.g. Fanconi syndrome and isolated
renal phosphate loss from various forms of hypophospha-
taemic rickets) and a value above the normal range suggests
inappropriate renal Pi retention (as that occurs in hypo-
parathyroidism or dietary phosphate restriction).
Hypophosphataemic rickets
Table 1 provides a summary of the various forms of
hypophosphataemic rickets. The list is not complete, but it
does cover the major categories. Hypophosphataemic
rickets due to decreased intestinal absorption either because
of a low dietary intake or the prolonged ingestion of
antacids will not be discussed further, as these do not
involve a primary defect in renal Pi handling. This review
concentrates on those conditions associated with isolated
renal tubular Pi loss rather than diseases associated with
complex renal tubular defects, such as in the Fanconi
syndrome (OMIM 134600), Lowe syndrome (OMIM
309000) [2], Dent disease (OMIM 300009) [2]o ra sa
result of ifosfamide nephrotoxicity [22].
Numerous diseases are associated with rickets and
increased renal Pi loss; however, it is the isolated
phosphaturic entities that have attracted the most attention
over the past decade, as the isolation of the genetic
mutations responsible for their pathogenesis has resulted
in a new understanding of the hormonal axis between bone
mineralisation, renal Pi handling and vitamin D metabolism
(Table 2).
The best known and most common of the inherited
isolated proximal tubular defects associated with rickets is
X-linked hypophosphataemic rickets (XLH) (OMIM
307800). This disease usually presents clinically in the first
two years of life with short stature, bowing of the legs,
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ria, normocalcaemia and normal or nearly-normal PTH with
inappropriately low or normal 1,25-(OH)2D concentrations.
Hypophosphataemia develops within the first few months
of life and is, thus, a useful biochemical test in young
infants who might be suspected of inheriting the abnormal
gene from an affected parent. One of the most striking and
distinctive features of XLH on bone histology (besides
osteomalacia) is the presence of hypomineralised peri-
osteocytic lesions in cortical bone. Although it was
hypothesised that a mutation in one of the genes encoding
for a renal Pi transporter would be found, this eventually
proved not to be the case. Rather, mutations in the PHEX
gene (phosphate-regulating gene with homologies to endo-
peptidases on the X-chromosome) were discovered in the
majority of patients [23]. The encoded endopeptidase
(PHEX) is membrane-bound and expressed mainly by
osteoblasts in bone and odontoblasts in teeth, with no
expression in the kidney [18]. This apparently surprising
finding is in keeping with experiments using the mouse
homologue of XLH, the Hyp mouse, in which convincing
evidence for a circulating factor causing the renal Pi loss in
the disease has been found [16]. It was, thus, hypothesised
that PHEX is involved in the catabolism of a phosphaturic
factor (phosphatonin) and the initial substrate candidate was
thought to be FGF23. However, a number of laboratories
have been unable to show that FGF23 is the substrate for
PHEX; thus, it is now believed that PHEX may prevent the
cleavage of an intermediate, such as matrix extracellular
phosphoglycoprotein (MEPE), which controls circulating
levels of FGF23 [6]. Inactivating mutations of PHEX, thus,
result in an increase in circulating concentrations of FGF23
with resultant phosphaturia [28]. Although FGF23 concen-
trations are not invariably increased in XLH, an inverse
relationship between FGF23 and the degree of hypophos-
phataemia has been found [25]. More recent evidence
indicates that elevated FGF23 plays a central role in
hypophosphataemia, disturbed vitamin D metabolism and
the development of osteomalacia and rickets characteristic
of XLH [27]. However, it is unclear whether the bone
disease and, in particular, the peri-osteocytic lesions are a
direct or indirect effect of FGF23.
Table 2 The genetic abnormalities associated with the various forms of hypophosphataemic rickets
Disease Gene
involved
Gene product Serum FGF23 Serum 1,25(OH)2D
X-linked hypophosphataemic
rickets
PHEX Inactivating mutation in
PHEX (endopeptidase)
Generally increased Within normal
range or decreased
Autosomal dominant
hypophosphataemic rickets
FGF23 Activating mutation in
FGF23 (phosphatonin)
Variable—may be increased
during symptomatic disease
Decreased
Autosomal recessive
hypophosphataemic rickets
DMP1 Inactivating mutation in DMP1
(involved in mineralisation)
Increased Within normal
range
Hereditary hypophosphataemic
rickets with hypercalciuria
SLC34A3 Inactivating mutation in NaPi-IIc
(renal Na-Pi cotransporter)
Not known Elevated
Table 1 A classification of the various forms of hypophosphataemic rickets
Decreased gastrointestinal Pi absorption Isolated renal phosphate leak Renal tubular disorders associated with Pi leak
Decreased dietary intake: Breast-fed
very-low-birthweight infants
Isolated phosphaturia: Phosphaturia, calciuria plus acidosis:
Distal renal tubular acidosis
Impaired intestinal absorption:
Prolonged antacid use
X-linked hypophosphataemic rickets (XLH) Phosphaturia, aminoaciduria, acidosis,
glucosuria, plus electrolyte disturbances:
Autosomal dominant hypophosphataemic
rickets (ADHR)
Fanconi syndrome (primary and secondary)
Autosomal recessive hypophosphataemic
rickets (ARHR)
Dent disease
Tumour-induced rickets (TIO) Lowe syndrome
Polyostotic fibrous dysplasia Ifosfamide toxicity
Neurocutaneous syndromes
Phosphaturia plus calciuria:
Hereditary hypophosphataemic rickets
with hypercalciuria
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may, in the long-term, offer a possibility of more effective
therapeutic management of the disease. However, in the
short-term, the new discoveries underline the evidence that
current forms of treatment with calcitriol and phosphate
supplements only partially address some of the defects in
the disease (hypophosphataemia and low to normal 1,25
(OH)2D concentrations), but do not alter the disturbed
underlying mechanisms, such as elevated FGF23 and
MEPE levels and the peri-osteocytic mineralisation defects.
Further, they provide a possible scientific basis for the often
poor response to treatment in subjects with XLH who may
have radiographic evidence of healing of the rachitic
lesions, but in whom osteomalacia persists, although at a
reduced severity. These findings raise concerns about the
possible role of treatment (calcitriol) in stimulating FGF23
concentrations and, thus, increasing renal Pi loss, inducing
a vicious cycle of increasing Pi supplements, increasing
secondary hyperparathyroidism and further Pi loss.
Autosomal dominant hypophosphataemic rickets (ADHR)
(OMIM193100)isaveryrarecauseofrickets,whichpresents
with variable penetrance and age of clinical onset. Although
superficially the disease presents in young children with
similar features to XLH (renal phosphate wasting, rickets and
lower limb deformities), in older female patients, features of
muscle weakness and bone pain may predominate [3].
Furthermore, a number of older subjects have been reported
to become asymptomatic with time. The importance of
ADHR in clinical paediatrics was established when it
became the first disease shown to be associated with
abnormalities of FGF23. This discovery has resulted in an
enormous flurry of research into the role of FGF23 and other
putative phosphatonins in Pi homeostasis and the control of
bone mineralisation. The mutations described in this condi-
tion have all been associated with amino acid substitutions at
a protease cleavage site in the FGF23 molecule, which result
in the mutant FGF23 being resistant to cleavage. The mutant
FGF23 would, thus, be expected to have a longer circulating
half-life than the wild type and be associated with higher
serum concentrations. A recent report found that FGF23
values were, surprisingly, not consistently elevated in
patients with ADHR and that serum concentrations fluctuat-
ed between normal and elevated values, depending on
whether or not the individual subject was hypophosphatae-
mic (symptomatic) [9].
Autosomal recessive hypophosphataemic rickets (ARHR)
(OMIM 241520) is another rare form of hypophosphataemic
rickets whose genetic mutation has recently been described
[26]. Inactivating mutations of the dentin matrix protein-1
(DMP1) gene result in a phenotype similar to that seen in
XLH. It appears that the biochemical features of hypophos-
phataemia, renal phosphate loss and inappropriately low 1,25
(OH)2D, are due to the secondary elevation of FGF23
concentrations. The clinical presentation is, surprisingly, not
found at birth, but affected individuals present later during
childhood and even in adulthood. As with PHEX and
FGF23, DMP1 is highly expressed in cells of the osteo-
blasts/osteocyte lineage. However, the interrelationships
between these three proteins are unclear. It does appear that
DMP1 normally decreases FGF23 concentrations, as FGF23
concentrations are elevated in ARHR [21].
Tumour-induced osteomalacia/rickets (TIO) is a para-
neoplastic syndrome, characterised by small tumours of
mesenchymal origin (generally diagnosed as haemangio-
pericytomas or non-ossifying fibromas) causing rickets and
osteomalacia through the secretion of phosphatonins, which
results in hypophosphataemia, renal phosphate wasting and
rickets/osteomalacia. Although the disease has been de-
scribed mainly in adult subjects, paediatric patients have
been reported [4]. Several striking features are helpful in
differentiating this condition from the other hypophospha-
taemic syndromes: clinical features include severe muscle
weakness, marked bone demineralisation and severe oste-
omalacia, and biochemically, besides the typical features of
hypophosphataemic rickets, 1,25(OH)2D concentrations are
markedly suppressed. The majority of tumours are small
and benign and may be found anywhere in soft-tissue or
bone, which make detection very difficult. Several secreted
factors have been proposed to be responsible for the
syndrome. These include FGF23, MEPE and frizzled
related protein-4 (FRP4) [27], with FGF23 being the most
often studied. Serum levels of FGF23 are found to be
elevated in most but not all patients with proven TIO.
Removal of the tumour results in a rapid decline in FGF23
concentrations and a restoration of normal biochemistry and
healing of the osteomalacia/rickets.
As mentioned earlier, the detection of a suspected
tumour is notoriously difficult. However, the expression
of somatostatin receptors by the tumours has resulted in the
recent development of
111In-octreotide scintigraphy [7, 15],
which, coupled with computed tomography (CT) scanning,
can accurately detect and localise the tumour (Fig. 1).
Further, in those patients in whom the tumour cannot be
found or removed because of its situation, subcutaneous
octreotide therapy may result in a reversal of the biochem-
ical abnormalities.
A number of other conditions, such as polyostotic
fibrous dysplasia (including the McCune-Albright syn-
drome) and several neurocutaneous syndromes (e.g. linear
nevus sebaceous syndrome), may also be associated with
hypophosphataemic rickets. Recent evidence indicates that
hypophosphataemia and rickets are probably due to the
over-expression of FGF23 in the lesions [8, 19].
Hereditary hypophosphataemic rickets with hypercalciu-
ria (HHRH) (OMIM 241530) is a recessively inherited
disorder, whose genetic mutations have only recently been
496 Eur J Pediatr (2008) 167:493–499identified [14]. Mutations involve the SLC34A3 gene,
which encodes for NaPi-IIc (Na-dependent Pi cotransporter
found in the proximal renal tubule). The condition can be
readily differentiated from other forms of rickets associated
with renal phosphate wasting, as the disease is associated
with hypercalciuria (>0.60 mmol calcium:mmol creatinine)
and elevated 1,25(OH)2D concentrations. Unlike the other
forms of hypophosphataemic rickets described above,
HHRH is the only one in which there is a primary defect
in Pi transport across the renal tubular cells. Thus, the body
responds appropriately to the resultant hypophosphataemia,
with stimulation of 1 alpha-hydroxylase activity and a
consequent rise in 1,25(OH)2D. The latter increases both
calcium and phosphate intestinal absorption, which results
in hypercalciuria and the suppression of PTH. The
importance of understanding the pathogenesis of these
biochemical changes is that phosphate supplementation
alone results in a correction of the biochemical perturba-
tions. There is no need for calcitriol supplementation, as the
1,25(OH)2D concentrations are already elevated.
Tying the strands together
It is clear that FGF23 plays a central role in the pathogenesis
of hypophosphataemia, depressed 1,25-(OH)2D concentra-
tions, osteomalacia and rickets in the majority of the forms
of rickets described above. Elevated concentrations of
FGF23 internalise and reduce the NaPi-IIa and c cotrans-
porters in the proximal renal tubule, reducing Pi reabsorp-
↑ FGF23
↓ serum Pi
+
--
↓  1,25-(OH)2D
KIDNEY BONE
Osteomalacia
--
↓ serum Ca
↑ PTH
--
+
--
The effects of ↑ FGF23
Feed back loops
Rickets
XLH
ADHR
ARHR
TIO
↓ Pi absorption
↓ Ca absorption
GIT
↑ Pi Excretion
↓ 1α-hydroxylase
Fig. 2 The effects of increased
FGF23 on bone and mineral
homeostasis. Abbreviations:
ADHR=autosomal dominant
hypophosphataemic rickets;
ARHR=autosomal hypophos-
phataemic rickets; Ca=calcium;
FGF23=fibroblast growth factor
23; Pi=inorganic phosphate;
PTH=parathyroid hormone;
TIO=tumour-induced
osteomalacia; XLH=X-linked
hypophosphataemic rickets;
1,25-(OH)2D=1,25 dihydroxyvi-
tamin D; –, suppression; +,
stimulation; ↑, increased; ↓,
decreased
Fig. 1 Co-localisation of an
osteomalacia-inducing tumour
in the distal metaphysis of the
left femur using
111In-octreotide
scintigraphy and computed to-
mography (CT) scanning in a
26-year-old subject who had
presented at the age of 16 years
with severe hypophosphataemic
rickets and multiple fractures
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reducing 1,25-(OH)2D and serum Pi concentrations (Fig. 2)
[11]. The resultant low serum Pi concentrations may be
directly responsible for the rachitic changes at the growth
plate, but it is likely that FGF23 has a direct effect on the
mineralisation of newly formed osteoid at the trabecular
bone surface, resulting in the features of osteomalacia [17].
However, the mechanisms of control of FGF23 and its role
in normal Pi homoeostasis are unclear at present. Whether
or not FGF23 is involved in the day to day control of serum
Pi in response to dietary Pi changes remains controversial, as
some studies have shown a relationship between FGF23 and
dietary or serum Pi [5] and others have not [10, 12]. Both
PTH and 1,25-(OH)2D increase FGF23 production, which
helps to reduce the Pi load induced by increased intestinal
Pi absorption and bone resorption associated with elevated
levels of the two former hormones. It is of interest that the
mRNA of all three factors (FGF23, PHEX and DMP1)
involved in the pathogenesis of hypophosphataemic rickets
are highly expressed in cells of the osteoblasts/osteocyte
lineage. Thus, bone plays a central role in FGF23 control
and plays an important part in the newly described kidney–
intestine–bone hormonal axis controlling Pi homeostasis
and bone mineralisation. It is likely that PHEX controls
FGF23 production indirectly, possibly through its binding
of MEPE [20], although this has not been confirmed [13].
DMP1 appears to suppress FGF23 production directly [17].
Although considerable advances have been made in
understanding the control of these bone/matrix proteins,
there is still much to be learned about the interplay of these
various factors, how they are controlled and the role they
play in normal mineral and bone homeostasis.
Conclusions
Although the individual forms of hypophosphataemic rickets
are relatively uncommon in childhood (with the exception of
X-linked hypophosphataemic rickets [XLH]), the recent
discoveries of their genetic defects have resulted in a greater
understanding of the complexities surrounding inorganic
phosphate (Pi) homeostasis and bone mineralisation. Further,
they have provided the paediatrician with a better understand-
ing of the deficiencies in current treatment options, as, in the
majority of conditions, the current therapy does not address
the basic defects. On the other hand, we should be optimistic
that new and more effective treatment options will emerge as
our understanding of the complex processes involved become
greater and new drugs are synthesised to alter the deranged
homeostatic mechanisms.Afurther spin-offfromthe renewed
interest in the syndromes has been the development of better
diagnostic procedures for the detection of phosphatonin-
secreting tumours.
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